XLS |
Internal audits on corruption and Human Rights Charter |
||||||||||||||
|
|
|
|
|
|
|||||||||
|
2014 |
2015 |
20161 |
2017 |
2017 |
|||||||||
|
||||||||||||||
Number of audits relating to corruption |
36 |
49 |
55 |
50 |
13 |
|||||||||
% of audits relating to corruption |
68 |
64 |
68 |
65 |
17 |
|||||||||
Number of audits relating to the workplace requirements of our Human Rights Charter |
32 |
41 |
47 |
45 |
12 |
In 2017, we audited 16% of all Group subsidiaries (status June 2017, excluding minority holdings), covering approximately 30% of all sales generated between the third quarter of 2016 and the second quarter of 2017.
In 2017, during 45 of our audits conducted in 22 countries, we additionally reviewed workplace parameters as per our Human Rights Charter. No violations were identified.
XLS |
Reported compliance violations |
||||||||||||
|
|
|
|
|
|
|||||||
|
2014 |
2015 |
20161 |
2017 |
2017 |
|||||||
|
||||||||||||
Total number of reported compliance violations |
|
|
|
|
|
|||||||
Number of reported compliance incidents |
26 |
33 |
36 |
39 |
1 |
|||||||
Number of confirmed cases |
11 |
8 |
12 |
14 |
1 |
|||||||
confirmed cases by category |
|
|
|
|
|
|||||||
Violation of the Human Rights Charter |
1 |
0 |
2 |
0 |
0 |
|||||||
Bribery and Corruption |
2 |
0 |
2 |
1 |
0 |
|||||||
Violation of the Pharmaceutical Guidelines |
2 |
2 |
4 |
2 |
0 |
|||||||
Violation of Data Privacy and Confidentiality Guidelines |
0 |
1 |
0 |
2 |
1 |
|||||||
Manipulation of Business Documents |
0 |
0 |
2 |
1 |
0 |
|||||||
Violation of cartel laws and fair competition rules |
0 |
1 |
0 |
0 |
0 |
|||||||
Infringements in the areas of finance, accounting and banking |
0 |
0 |
0 |
0 |
0 |
|||||||
Theft and fraudulent Actions against the Group |
1 |
2 |
1 |
1 |
0 |
|||||||
Other violations of Compliance Principles for the relations with Business Partners of the Group |
0 |
0 |
1 |
2 |
0 |
|||||||
Other violations of values, internal guidelines or legal requirements |
5 |
2 |
0 |
5 |
0 |
In 2017 there was a total of 14 confirmed compliance cases, 2 of which were already reported in 2016, but closed in 2017.
XLS |
Compliance training |
||||||||||||||||||
|
|
|
|
|
|
|||||||||||||
|
20141 |
2015 |
20162 |
2017 |
2017 |
|||||||||||||
|
||||||||||||||||||
Total number of persons trained on anti-corruption guidelines3 |
7,519 |
20,404 |
29,764 |
17,044 |
2,326 |
|||||||||||||
Total number of employees trained on anti-corruption guidelines |
5,496 |
17,378 |
25,889 |
13,345 |
1,450 |
|||||||||||||
% of employees trained on anti-corruption |
14 |
43 |
51 |
25 |
14 |
|||||||||||||
by employee category |
|
|
|
|
|
|||||||||||||
Number of Role 2+ employees trained on anti-corruption |
3,071 |
12,747 |
14,379 |
7,080 |
635 |
|||||||||||||
% of Role 2+ employees trained on anti-corruption |
17 |
64 |
84 |
27 |
13 |
|||||||||||||
% of employees below Role 2 trained on anti-corruption |
12 |
22 |
34 |
24 |
15 |
|||||||||||||
by region (%)4 |
|
|
|
|
|
|||||||||||||
Europe |
– |
– |
54 |
18 |
14 |
|||||||||||||
North America |
– |
– |
57 |
46 |
not applicable |
|||||||||||||
Asia-Pacific (APAC) |
– |
– |
38 |
25 |
not applicable |
|||||||||||||
Latin America |
– |
– |
52 |
19 |
not applicable |
|||||||||||||
Middle East and Africa (MEA) |
– |
– |
66 |
29 |
not applicable |
In order to address the special responsibility held by management personnel, as well as by staff with HR responsibility, these employees are increasingly receiving training on anti-corruption guidelines. This applies to all employees rated Role 2+.
Our compliance and anti-corruption principles are communicated to all our business partners, who undergo a Business Partner Risk Management (BPRM) process.
Training increased in 2016 due to the initial integration of employees of Sigma-Aldrich, a company acquired at the end of 2015.
XLS |
Legal actions |
||||||||||||||
|
|
|
|
|
|
|||||||||
|
2014 |
20151 |
2016 |
2017 |
2017 |
|||||||||
|
||||||||||||||
Total number2 of legal actions pending or completed (for anti-competitive behavior, violations of anti-trust or violations of monopoly legislation) |
2 |
2 |
2 |
3 |
2 |
|||||||||
pending |
2 |
2 |
2 |
3 |
2 |
|||||||||
completed |
0 |
0 |
0 |
0 |
0 |
For further information please see our annual reports:
- Annual Report 2014, pages 130-131 and pages 213-215, no. 48
- Annual Report 2015, pages 128-129 and pages 212-213, no. 27
- Annual Report 2016, pages 135-136 and pages 228-229, no. 26
- Annual Report 2017, pages 148-150 and pages 252-254, no. 27